OncoPep is developing the adoptive T cell therapy as part of a licensing agreement with MANA Therapeutics. MANA's EDIFY platform is specifically designed to train T cells to target multiple tumor associated antigens, harnessing the patient's immune system for an approach that targets a broader set of antigens expressed by the tumor.
In this collaboration, a patient's T cells will be trained ex vivo with EDIFY to target the antigens, XBP1, CD138 and CS1, which are highly over-expressed in multiple myeloma and other solid tumors.
OncoPep's lead therapeutic cancer vaccine candidate, PVX-410, is also designed to train T cells to target XBP1, CD138 and CS1 and could potentially be used in combination with the adoptive T cell therapy.
This new adoptive T cell therapy approach has the potential to provide more persistent and durable control over tumor cell growth and could prevent the progression of cancer and improve quality of life for patients with multiple myeloma.
Multiple myeloma is a debilitating type of hematologic cancer that affects plasma cells. It is the second most common blood cancer, accounting for 13% of all hematologic cancers and 1% of all cancer deaths.
MM is characterized by a proliferation of malignant plasma cells, which may in turn interfere with the normal production of blood cells.
MM causes significant side effects, such as debilitating bone pain and fractures, anemia, leukopenia, thrombocytopenia, renal insufficiency and failure, hypercalcemia and increased chance of infection.
OncoPep is developing targeted immunotherapeutics to prevent the progression of cancer, prolong survival and restore the quality of life of patients. OncoPep's lead program is an investigational, multi-peptide therapeutic vaccine being evaluated in treating smoldering multiple myeloma.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine